NCT02608411 2023-10-13
TIMES
Istituto Oncologico Veneto IRCCS
Phase 2 Terminated
Clinical Trials
5 trialsNCT01055067 2021-04-06
ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors
Daiichi Sankyo
Phase 2 Terminated
NCT01244191 2021-04-06
Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer
Daiichi Sankyo
Phase 3 Terminated
NCT01377376 2016-12-07
ATTENTION
Kyowa Kirin Co., Ltd.
Phase 3 Terminated
NCT01861301 2016-10-24
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
National Cancer Institute (NCI)
Phase 2 Terminated